HBI Deals+Insights / M&A/IPOs
The IPO of international dialysis provider Diaverum by owner Bridgepoint is likely to have been pushed back to 2021, we are told. While dialysis volumes have been largely unaffected by the pandemic, lockdowns and travel restrictions may have hit its ability to reach full-year growth targets.